|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:brand
|
gptkb:Gralise
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:class
|
Anticonvulsant
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:clinical_use
|
Chronic pain management
|
|
gptkbp:contraindication
|
Hypersensitivity to gabapentin
|
|
gptkbp:dosage_form
|
300 mg, 600 mg
|
|
gptkbp:effective_date
|
FDA approved
2011-05-25
|
|
gptkbp:excretion
|
Renal
|
|
gptkbp:form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gralise
|
|
gptkbp:indication
|
Diabetic neuropathy
Postherpetic neuralgia
|
|
gptkbp:ingredients
|
gptkb:Gabapentin
|
|
gptkbp:interacts_with
|
Antacids
Alcohol
Opioids
|
|
gptkbp:invention
|
2026-05-25
|
|
gptkbp:lifespan
|
5 to 7 hours
|
|
gptkbp:manufacturer
|
Depomed, Inc.
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:metabolism
|
Hepatic
|
|
gptkbp:packaging
|
Blister pack
|
|
gptkbp:patient_population
|
Adults
|
|
gptkbp:previous_name
|
gptkb:Gabapentin
|
|
gptkbp:provides_guidance_on
|
Neuropathic pain management guidelines
|
|
gptkbp:research
|
Efficacy in diabetic neuropathy
Gabapentin and opioid combination therapy
Gabapentin for neuropathic pain
Gabapentin in postherpetic neuralgia
Long-term safety of gabapentin
|
|
gptkbp:route_of_administration
|
Oral
|
|
gptkbp:service_frequency
|
Once daily
|
|
gptkbp:side_effect
|
gptkb:Nausea
Dizziness
Fatigue
Mood changes
Weight gain
Somnolence
Vision changes
Coordination problems
Memory problems
Peripheral edema
|
|
gptkbp:storage
|
Room temperature
|
|
gptkbp:tablet_color
|
gptkb:White
|
|
gptkbp:tablet_imprint
|
Gralise 300 mg
|
|
gptkbp:tablet_shape
|
Round
|
|
gptkbp:type_of_care
|
Once daily dosing improves adherence
|
|
gptkbp:used_for
|
Neuropathic pain
|
|
gptkbp:bfsParent
|
gptkb:Neurontin
|
|
gptkbp:bfsLayer
|
7
|